| Project/Area Number |
23591728
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
HATTA Kotaro 順天堂大学, 医学部, 准教授 (90337915)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KISHI Yasuhiro 日本医科大学, 医学部, 教授 (60256930)
ODAWARA Toshinari 横浜市立大学, 大学病院, 准教授 (00244426)
TAKEUCHI Takashi 東京医科歯科大学, 医歯(薬)学総合研究科, 講師 (70345289)
SUGITA Manabu 順天堂大学, 医学部, 准教授 (20322414)
USUI Chie 順天堂大学, 医学部, 准教授 (70453587)
KAMIJO Yoshito 北里大学, 医学部, 教授 (90255266)
MACHIDA Yutaka 順天堂大学, 医学部, 准教授 (90317470)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKAMURA Hiroyuki 金沢大学, 医学部, 教授 (30231476)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | せん妄 / 予防 / 予測 / 治療 / ラメルテオン / メラトニン / 抗精神病薬 / ナチュラル・キラー細胞 / ナチュラルキラー細胞 / ランダム化比較試験 / 嚥下性肺炎 / コンジョイント分析 / リスペリドン / クエチアピン / ランダム化臨床試験 / インターロイキン1β |
|---|
| Outline of Final Research Achievements |
First, we have demonstrated preventive effects of ramelteon, a melatonin agonist, on delirium through a randomized placebo-controlled trial. This finding supports a possible pathogenic role of melatonin neurotransmission in delirium. This accomplishment may provide a paradigm shift from treatment to prevention in clinical practice of delirium. Second, we have demonstrated the predictive value of a change in natural killer cell activity for delirium. The importance of delirium prediction may increase as we have developed an effective prevention method. Third, we have demonstrated that in the general hospital setting under management including fine dosage adjustment in individual patients and the early detection of side-effects, antipsychotics have a low risk in the treatment of patients with delirium, and have high efficacy.
These findings such as prevention, prediction, and treatment will provide clinical guidelines for delirium.
|
